Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level
Momenta Pharmaceuticals (NASDAQ: MNTA) shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's (NYSE: TEVA) patents on Copaxone in 2015 and partly invalidating its 2014 patents.
Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal.
If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike.
Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share.
Gal rates Momenta at Outperform with a $20 price target.
Latest Ratings for MNTA
|Nov 2015||Barclays||Initiates Coverage on||Equal-weight|
|Nov 2015||JP Morgan||Initiates Coverage on||Overweight|
|Nov 2015||Leerink Swann||Maintains||Outperform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.